iRhythm Technologies
Open
$113.02
Prev. Close
$112.99
High
$113.71
Low
$112.98
Market Snapshot
$3.67B
-132.2
-3.64
$591.84M
iRhythm Holdings, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. The company is headquartered in San Francisco, California and currently employs 2,400 full-time employees. The company went IPO on 2016-10-20. The firm's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The firm provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
iRhythm Holdings, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. The company is headquartered in San Francisco, California and currently employs 2,400 full-time employees. The company went IPO on 2016-10-20. The firm's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The firm provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Recently from Cashu
Missing article stalls iRhythm Technologies summary; summariser requests source text and word-length confirmation
iRhythm disclosure gap slows newsroom summaries A request to summarise a pre-market roundup titled “Companies Reporting Before The Bell” is stalling because the source article is not provided, and tha…
iRhythm Technologies Under Investigation for Misrepresentation of Zio AT Monitor Capabilities
iRhythm Technologies Faces Allegations Over Misrepresentation of Zio AT Monitor iRhythm Technologies, Inc. is currently under scrutiny due to a federal securities investigation led by Kuehn Law, PLLC,…
iRhythm Technologies Under Legal Investigation for Alleged Misrepresentation of Zio AT Monitor
iRhythm Technologies Faces Legal Scrutiny Over Allegations of Misrepresentation iRhythm Technologies, Inc. is currently embroiled in a federal securities lawsuit that raises serious concerns about cor…
iRhythm Technologies Under Legal Investigation for Alleged Misrepresentations Regarding Zio AT Monitor
iRhythm Technologies Faces Legal Scrutiny Over Alleged Misrepresentations iRhythm Technologies, Inc., known for its innovative cardiac monitoring solutions, is currently under investigation by Kuehn L…